OTCPK:NEPTF - Post by User
Post by
gwrbion Oct 18, 2013 2:13pm
311 Views
Post# 21828250
Bio-tech risks
Bio-tech risks
I think the fallout from the Amarin debacle is far reaching. The FDA clearly changed the game for Amarin, and set Amarin up for failure at the Adcom. This renewed uncertainty towards the FDA, and its changing mandate and process, together with immense (and increasing) costs of approving drugs, plus this whole 'can anyone actually prove lowering cholesterol can save lives, etc.?" is causing a deep fog over the whole space right now.
As for Acasti's CaPre, it could and should be a wonderdrug, but the market sees knew uncertainty....
Acasti's SP won't be heading too far north until management comes clean with a financing strategy. The company has tremendous prospects, but a diluting new financing may be coming soon.
One last thought. The Amarin case should be a lesson to all smaller bio-techs. Don't be greedy, don't try to go it alone, and partner sooner than later with better capitalized pharma companies who are desperate to fill their drug pipelines, and who have the capital, the connections, the expertise, and the distribution channels to do it.
Are you listening Henri?